Comparable stake leader
Andrew John Partridge
SEC ownership of Turning Point Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001595893.
Disclosed value leader
Andrew John Partridge
Comparable rows
0/3
Latest evidence
09 Feb 2022
- Parsed ownership sources
-
3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Andrew John Partridge
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
09 Feb 2022
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001595893
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Turning Point Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Andrew John Partridge
Disclosed value leader
Andrew John Partridge
Comparable rows
0/3
Latest evidence
09 Feb 2022
3/4/5
Highest disclosed value: $2,915,436
3 rows are not safely comparable across share classes.
Quick read
Andrew John Partridge has the largest disclosed position value at $2.92M.
0 of 3 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Andrew John Partridge's linked filing trail.
Disclosed position value
Top 3
Andrew John Partridge
$2.92M
Annette North
$2.13M
Siegfried Reich
$1.29M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-3 of 3 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Andrew John Partridge |
3/4/5
EVP & Chief Commercial Officer
|
—
mixed-class rows
|
$2,915,436
96,961 shares
mixed-class rows
|
— | 09 Feb 2022 |
| Annette North |
3/4/5
EVP & General Counsel
|
—
mixed-class rows
|
$2,126,404
86,579 shares
mixed-class rows
|
— | 09 Feb 2022 |
| Siegfried Reich |
3/4/5
EVP & Chief Scientific Officer
|
—
mixed-class rows
|
$1,293,140
65,848 shares
mixed-class rows
|
— | 09 Feb 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 14 Oct 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to Turning Point Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
Andrew John Partridge
Net 12M change
$0
Latest report
17 Aug 2022
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Andrew John Partridge | EVP & Chief Commercial Officer | $2,915,436 | Mixed | 09 Feb 2022 | ||
| Annette North | EVP & General Counsel | $2,126,404 | Mixed | 09 Feb 2022 | ||
| Siegfried Reich | EVP & Chief Scientific Officer | $1,293,140 | Mixed | 09 Feb 2022 | ||
| Carol Giltner Gallagher | Director | Mixed | 17 Aug 2022 | |||
| Barbara W. Bodem | Director | Mixed | 17 Aug 2022 | |||
| Mohammad Hirmand | EVP and Chief Medical Officer | Mixed | 17 Aug 2022 | |||
| Steve M. Sabus | SVP & Chief Commercial Officer | Mixed | 17 Aug 2022 | |||
| Garry A. Nicholson | Director | Mixed | 17 Aug 2022 | |||
| Kyri K. van Hoose | Principal Accounting Officer | Mixed | 14 May 2021 | |||
| Simeon George | Director | Mixed | 17 Aug 2022 | |||
| Mark J. Alles | Director | Mixed | 17 Aug 2022 | |||
| Patrick Machado | Director | Mixed | 17 Aug 2022 | |||
| Athena Countouriotis | President & CEO, Director | Mixed | 17 Aug 2022 | |||
| Paolo Tombesi | EVP & Chief Financial Officer | Mixed | 17 Aug 2022 | |||
| Brian Sun | SVP & General Counsel | Mixed | 17 Aug 2022 |
Recent insider transactions for Turning Point Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.